Boris Reva

51.8k citations

50 papers · 16.9k indexed · 4 hit papers · h-index 22

Impact in

Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
Oncology top 0.5%
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers

Papers in

Cancer Research 11
- Cancer Genomics and Diagnostics 8
Aging 1

Co-authors: Chris Sander Yevgeniy Antipin Nikolaus Schultz Anders J. Skanderup Erik Larsson Jianjiong Gao Benjamin Groß Arthur P. Goldberg
Journals: Protein Engineering Design and Selection (7 papers)Proteins Structure Function and Bioinformatics (5 papers)Blood (2 papers)Clinical Cancer Research (2 papers)Journal of Thoracic Oncology (2 papers)
Partner nations: United States Russia Canada

In The Last Decade

Boris Reva

49 papers receiving 16.7k citations

Hit Papers

align trajectories log scale

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics 2013 · 348 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Molecular Cancer Therapeutics
2012 Cancer Discovery
2011 Nature Genetics
2011 Nucleic Acids Research

Peers

Countries citing papers authored by Boris Reva

Since Specialization

Citations

This map shows the geographic impact of Boris Reva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Reva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Reva more than expected).

Fields of papers citing papers by Boris Reva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Reva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Reva. The network helps show where Boris Reva may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Boris Reva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Boris Reva Line = papers co-authored together Boris Reva links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality ERJ Open Research ·Xiaoyu Song, A. Materia, Boris Reva, Himanshu Joshi, Anna Calinawan, Madhu Mazumdar, Juan P. Wisnivesky, Emanuela Taioli, Pei Wang, Rajwanth Veluswamy	2021	10
2	Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study PLoS Medicine ·Navya Nair, Olga Camacho‐Vanegas, Dmitry Rykunov, Z. Jian, Sandra Catalina Camacho, Cassie Schumacher, Jonathan C. Irish, Timothy T. Harkins, Diego Marsicano, Saraswati Devi, Elena Pereira, Sviatoslav M. Kendall, G Misiti, Tamara Kalir, Robert Sebra, Boris Reva, Peter Dottino, John A. Martignetti	2016	69
3	Mutation Screening of Candidate Genes in Patients with Nonsyndromic Sagittal Craniosynostosis Plastic & Reconstructive Surgery ·Xiaoqian Ye, Audrey Guilmatre, Boris Reva, Inga Peter, Yann Heuzé, Joan T. Richtsmeier, Deborah Fox, Rhinda Goedken, Ethylin Wang Jabs, Paul A. Romitti	2016	19
4	Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21∗ in SCC progression Nature Cell Biology ·Yejing Ge, Liang Zhang, Maria Nikolova, Boris Reva, Elaine Fuchs	2015	50
5	Direct in Vivo RNAi Screen Unveils Myosin IIa as a Tumor Suppressor of Squamous Cell Carcinomas Science ·Daniel Schramek, Ataman Sendoel, Jeremy P. Segal, Slobodan Beronja, Evan Heller, Daniel Oristian, Boris Reva, Elaine Fuchs	2014	212
6	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking Clinical Cancer Research ·Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi	2014	106
7	Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib Journal of Thoracic Oncology ·Matthew D. Hellmann, Boris Reva, Helena A. Yu, Valerie W. Rusch, Naiyer A. Rizvi, Mark G. Kris, Maria E. Arcila	2014	22
8	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network Clinical Cancer Research ·A. Ari Hakimi, Irina Ostrovnaya, Boris Reva, Nikolaus Schultz, Ying‐Bei Chen, Mithat Gönen, Han Liu, Shugaku Takeda, Martin H. Voss, Satish K. Tickoo, Victor E. Reuter, Paul Russo, Emily H. Cheng, Chris Sander, Robert J. Motzer, James J. Hsieh	2013	267
9	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Molecular Cancer Therapeutics ·Maria E. Arcila, Khédoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi Hit paper breakdown →	2013	348
10	Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles Journal of Thoracic Oncology ·Natasha Rekhtman, Laetitia Borsu, Boris Reva, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi, Alexander Drilon	2013	5
11	Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif Nature Communications ·Mark P. Hamilton, Kimal Rajapakshe, Sean M. Hartig, Boris Reva, Michael D. McLellan, Cyriac Kandoth, Jun Li, Travis Zack, Preethi H. Gunaratne, David A. Wheeler, Cristian Coarfa, Sean E. McGuire	2013	91
12	The molecular diversity of Luminal A breast tumors Breast Cancer Research and Treatment ·Giovanni Ciriello, Rileen Sinha, Katherine A. Hoadley, Anders J. Skanderup, Boris Reva, Charles M. Perou, Chris Sander, Nikolaus Schultz	2013	100
13	p53 Regulates Hematopoietic Stem Cell Quiescence Cell stem cell ·Yan Liu, Shannon Elf, Yasuhiko Miyata, Goro Sashida, Yuhui Liu, Gang Huang, Silvana Di Giandomenico, Jennifer M. Lee, A DeBlasio, Sílvia Menéndez, Luis Rafael Muñoz de Morales Castro, Boris Reva, Andrew Koff, Stephen D. Nimer	2009	427
14	Threading with chemostructural restrictions method for predicting fold and functionally significant residues: Application to dipeptidylpeptidase IV (DPP‐IV) Proteins Structure Function and Bioinformatics ·Boris Reva, Alexei V. Finkelstein, Sid Topiol	2002	13
15	What is the probability of a chance prediction of a protein structure with an rmsd of 6 å? PubMed ·Boris Reva, Alexei V. Finkelstein, Jeffrey Skolnick	1998	186
16	Optimization of Protein Structure on Lattices Using a Self-Consistent Field Approach Journal of Computational Biology ·Boris Reva, Elena-Tatiana Huțu Dâlcu-Năstase, Alexei V. Finkelstein, Jeffrey Skolnick	1998	9
17	Search for the most stable folds of protein chains: I. Application of a self-consistent molecular field theory to a problem of protein three-dimensional structure prediction Protein Engineering Design and Selection ·Alexei V. Finkelstein, Boris Reva	1996	16
18	Search for the stable state of a short chain in a molecular field Protein Engineering Design and Selection ·Alexei V. Finkelstein, Boris Reva	1992	28
19	A new approach to the design of a sequence with the highest affinity for a molecular surface Protein Engineering Design and Selection ·Boris Reva, Alexei V. Finkelstein	1992	10
20	A search for the most stable folds of protein chains Nature ·Alexei V. Finkelstein, Boris Reva	1991	110

About Boris Reva

Boris Reva is a scholar working on Cancer Research, Aging, Molecular Biology, Genetics and Spectroscopy, having authored 50 papers that have together received 16.9k indexed citations. Recurring topics across this work include Protein Structure and Dynamics (18 papers), Cancer Genomics and Diagnostics (8 papers), RNA and protein synthesis mechanisms (8 papers), Enzyme Structure and Function (6 papers), Bioinformatics and Genomic Networks (6 papers), Machine Learning in Bioinformatics (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Computational Drug Discovery Methods (4 papers). The work is most often cited by research in Cancer Research (5.0k citations), Oncology (4.7k citations), Molecular Biology (11.3k citations), Pulmonary and Respiratory Medicine (4.3k citations) and Pathology and Forensic Medicine (1.5k citations). Boris Reva has collaborated with scholars based in United States, Russia and Canada. Frequent co-authors include Chris Sander, Yevgeniy Antipin, Nikolaus Schultz, Anders J. Skanderup, Erik Larsson, Jianjiong Gao, Benjamin Groß, Arthur P. Goldberg, Bülent Arman Aksoy and Michael Heuer. Their work appears in journals such as Protein Engineering Design and Selection, Proteins Structure Function and Bioinformatics, Blood, Clinical Cancer Research and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact